News

The FDA recently approved Lu 177 vipivotide tetraxetan for use in patients with metastatic castration-resistant prostate cancer.

In an interview with Targeted Oncology, Ravi Salgia, MD, PhD, discussed the research leading to the first-in-human study of LB-100 combined with chemotherapy or immunotherapy to address transformation to small cell lung cancer.

Charles Geyer, MD, discusses olaparib for the treatment of patients with BRCA-positive, HER2-negative high-risk early breast cancer as evaluated in the OlympiA study.

An application for approval has been submitted to the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.

Pembrolizumab and MRx0518 has shown clinical benefit in patients with renal cell carcinoma that have progressed on a prior immune checkpoint inhibitor.

Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.

The phase 3 CALLA study did not achieve its key end point of progression-free survival improvement with the addition of durvalumab to chemoradiotherapy in patients with locally advanced cervical cancer.

Nicholas J. Vogelzang, MD, discusses some of the approvals and different regimens seen in today’s renal cell carcinoma treatment landscape.

Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.

Chimeric antigen receptor expansion by day 10 could be an early biomarker to predict response and survival in patients with B-cell lymphoma.

During a debate at the Gastrointestinal Cancers Symposium, Florian Lordick, MD, argued that knowledge of PD-L1 expression level was needed before starting immune checkpoint inhibitor therapy. He was challenged by Aaron James Scott, MD, who argued that knowledge of PD-L1 is not necessary before initiating immune checkpoint inhibitor therapy.

Results from the phase 1b EQUATE study were favorable enough to initiate a phase 3 study, which will test itolizumab for the frontline treatment of acute graft-versus-host disease..

The FDA is no longer conducting a speedy review of the supplemental biologics license application for luspatercept-aamt as treatment for anemia in adults with non-transfusion-dependent beta thalassemia.

In an interview with Targeted Oncology, C.K. Wang, MD, discussed the importance of real-world data in oncology, the mission of COTA, and research the company has been a part of.

TST001 has shown to be safe in ongoing trials alone or in combination with chemotherapy and displayed encouraging anti-tumor activity signals in gastric cancer and other solid tumor patients expressing CLDN18.2.

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

The FDA has given the targeted inhibitor alrizomadlin a rare pediatric disease designation for the treatment of neuroblastoma.

Researchers found that depletion of naïve T cells from peripheral blood stem cell allografts results in very low incidences of severe acute and chronic graft-versus-host disease without reduced risk of relapse or nonrelapse mortality.

In an interview with Targeted Oncology following the tweet chat, Yelena Y. Janjigian, discussed the key takeaways from the discussion and highlighted the biomarkers and standard of care for the patient in this case.

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.

Michael Wang, MD, discusses the study design of the ongoing, multicenter, open-label study examining an acalabrutinib triplet in MCL.

The FDA has issued a complete response letter denying approval of sintilimab injection in combination with pemetrexed and platinum chemotherapy as frontline treatment for patients with nonsquamous non–small cell lung cancer.

With larotrectinib treatment, patients with advanced lung cancers whose tumors harbor NTRK gene fusions experienced durable responses, survival benefit, and a favorable safety profile.

Theodore W. Laetsch, MD, discusses various trials examining larotrectinib in patients with TRK fusion positive thyroid cancer.

Findings presented during the SGO Annual Meeting show that atezolizumab given prior to concurrent chemoradiation may be safe with immune modulating activity in patients with node-positive, locally advanced cervical cancer.

Haploidentical donor-derived allogeneic hematopoietic cell transplant appears to be feasible for patients with Philadelphia chromosome-positive chronic myeloid leukemia, similar to other donor types.

Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.

Treatment locations in New York, New Jersey, and Florida are recruiting patients with mall cell lung cancer to receive olaparib and low-dose radiotherapy in a phase 1 clinical trial.

Data from the SORAYA trial shows the use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer to result in meaningful anti-tumor activity, consistent safety, and favorable tolerability.